{
    "clinical_study": {
        "@rank": "107439", 
        "acronym": "MiHeart", 
        "arm_group": [
            {
                "arm_group_label": "Cell Therapy", 
                "arm_group_type": "Experimental", 
                "description": "Intramyocardial injection of autologous bone marrow-derived cells"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "No Intervention", 
                "description": "Saline injection"
            }
        ], 
        "brief_summary": {
            "textblock": "Patients with advanced coronary artery disease usually undergo incomplete myocardial\n      revascularization due to the extension and diffuseness of the disease, with very poor distal\n      arterial beds unsuitable for direct revascularization.\n\n      This study was designed to test the hypothesis that direct, intramyocardial injection of\n      autologous bone marrow cells may further improve myocardial perfusion  in patients\n      undergoing incomplete bypass surgery."
        }, 
        "brief_title": "Cell Therapy in Severe Chronic Ischemic Heart Disease", 
        "completion_date": {
            "#text": "July 2013", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Chronic Ischemic Heart Disease", 
            "Coronary Artery Disease", 
            "Angina Pectoris"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Angina Pectoris", 
                "Coronary Artery Disease", 
                "Myocardial Ischemia", 
                "Coronary Disease", 
                "Heart Diseases", 
                "Ischemia"
            ]
        }, 
        "detailed_description": {
            "textblock": "All eligible patients will undergo coronary artery bypass grafting (CABG) and, in previously\n      identified areas of viable, ischemic myocardium unsuitable for direct revascularization, be\n      randomized to either placebo (saline) or intramyocardial injection of bone marrow-derived\n      cells (BMC) during surgery.\n\n      During follow-up, myocardial perfusion assessment will be performed to determine the\n      improvement in treated areas compared to non-treated segments."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  symptoms of angina or angina equivalent\n\n          -  documented coronary artery disease (invasive angiography)\n\n          -  documented myocardial ischemia (stress echo, cardiac scintigraphy, or MRI)\n\n          -  unsuitable for complete myocardial revascularization (PCI or CABG) OR even if a\n             complete procedure in feasible, it is anticipated that myocardial perfusion may not\n             be restored due to poor distal beds\n\n        Exclusion Criteria:\n\n          -  severe LV dysfunction (EF < 25% on echo)\n\n          -  short life expectacy (below < 1 year)\n\n          -  diagnosis of cancer in the past 5 years\n\n          -  diagnosis of hematological diseases\n\n          -  diagnosis of severe heart disease of other etiologies including valvular heart\n             disease, Chagas' disease, etc)\n\n          -  diagnosis of acute coronary syndrome in the past 3 months\n\n          -  diagnosis of chronic kidney disease stage V requiring chronic dialysis"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "200", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 12, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01727063", 
            "org_study_id": "EMRTCC-ISQ2"
        }, 
        "intervention": {
            "arm_group_label": "Cell Therapy", 
            "description": "Intramyocardial injection of autologous bone marrow-derived cells", 
            "intervention_name": "Cell Therapy", 
            "intervention_type": "Procedure"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Chronic ischemic heart disease", 
            "Coronary artery disease", 
            "Angina pectoris", 
            "Myocardial ischemia", 
            "Cardiac surgery"
        ], 
        "lastchanged_date": "November 12, 2012", 
        "location": {
            "facility": {
                "address": {
                    "city": "Sao Paulo", 
                    "country": "Brazil", 
                    "state": "SP", 
                    "zip": "05403-000"
                }, 
                "name": "Heart Institute"
            }, 
            "investigator": {
                "last_name": "Luis Henrique W Gowdak, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Brazil"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy of Intramyocardial Injection of Autologous Bone-Marrow Cells in Patients With Severe, Chronic Ischemic Heart Disease Undergoing Coronary Bypass Surgery", 
        "other_outcome": {
            "description": "Angina functional class will be determined using the Canadian Cardiovascular Society classification.", 
            "measure": "Improvement in angina functional class", 
            "safety_issue": "No", 
            "time_frame": "1, 6 and 12 months"
        }, 
        "overall_contact": {
            "email": "meyri.vieira@incor.usp.br", 
            "last_name": "Meyrielli A Vieira", 
            "phone": "+55-11-2661-5000", 
            "phone_ext": "5377"
        }, 
        "overall_contact_backup": {
            "email": "luis.gowdak@incor.usp.br", 
            "last_name": "Luis Henrique Gowdak, MD, PhD", 
            "phone": "+55-11-2661-5000", 
            "phone_ext": "5929"
        }, 
        "overall_official": [
            {
                "affiliation": "Heart Institute", 
                "last_name": "Jose Eduardo Krieger, MD, PhD", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "Heart Institute", 
                "last_name": "Carlos Eduardo Rochitte, MD, PhD", 
                "role": "Study Chair"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Brazil: National Committee of Ethics in Research", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "July 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Patients will undergo myocardial perfusion assessment by MRI during pharmacological stress with adenosine or dipyridamole. Alternatively, cardiac scintigraphy can be used in patients with contra-indications to MRI.", 
            "measure": "Increase in myocardial perfusion", 
            "safety_issue": "No", 
            "time_frame": "1, 6 and 12 months"
        }, 
        "reference": {
            "PMID": "17233910", 
            "citation": "Tura BR, Martino HF, Gowdak LH, dos Santos RR, Dohmann HF, Krieger JE, Feitosa G, Vilas-Boas F, Oliveira SA, Silva SA, Bozza AZ, Borojevic R, de Carvalho AC. Multicenter randomized trial of cell therapy in cardiopathies - MiHeart Study. Trials. 2007 Jan 18;8:2."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01727063"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Ministry of Health, Brazil", 
            "investigator_full_name": "Dr. Lu\u00eds Henrique W. Gowdak", 
            "investigator_title": "Clinical Coordinator", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "LV function (global and regional) will be assessed by MRI.", 
            "measure": "Improvement in LV function", 
            "safety_issue": "No", 
            "time_frame": "1, 6 and 12 months"
        }, 
        "source": "Ministry of Health, Brazil", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Ministry of Health, Brazil", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2006", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2012"
    }
}